Targeting serotonin transporter boosts tumor-fighting T cells

In this issue of Cell, Yang and colleagues demonstrate that autocrine activation of serotonin receptors on tumor-infiltrating CD8(+) T cells enhances antitumor immunity. Modulating serotonin signaling may provide a new approach to therapy for cancer. Serotonin-targeting drugs such as SSRIs and others, developed to fight depression, may thus be repurposed for cancer immunotherapy.